A clinical trial has demonstrated that oVRcome, a virtual reality app developed in New Zealand for treating anxiety and phobias, significantly reduces symptoms of social anxiety.
Professor Cameron Lacey from the University of Canterbury led the study, collaborating with experts from the University of Otago. It stands as the largest virtual reality study to date focusing on Social Anxiety Disorder (SAD). The study underscores the potential role of virtual reality technology in addressing mental health issues. Participants in the trial comprised adults who were experiencing moderate to severe social anxiety, as measured by the Liebowitz Social Anxiety Scale (LSAS). These individuals were assigned to a waitlist-delayed treatment group and underwent evaluations at both 12 and 18 weeks.
The study's findings reveal that oVRcome reduced social anxiety symptoms by an average of 35.3% and achieved a 50% reduction by the 18-week mark. This performance resulted in an effect size more than double what is typically regarded as "highly effective" in mental health interventions. oVRcome integrates virtual reality exposure therapy with cognitive-behavioural therapy (CBT) principles, making it accessible via a smartphone. The app allows users to immerse themselves in 360-degree video scenarios, which replicate real-world social settings in a controlled and safe environment.
Dr. Cameron Lacey highlighted the significance of finding solutions for SAD, a condition characterised by the fear of social interaction and judgement, significantly affecting everyday life and well-being. "Our research highlights not only the positive outcomes of VR-based interventions but also the potential to meet a growing need in mental health care by overcoming common barriers to treatment," Dr. Lacey noted.
The availability of self-help apps designed to tackle anxiety has increased, but only 3.8% have undergone evaluation in controlled trials. Social Anxiety Disorder remains prevalent yet frequently untreated due to hurdles such as stigma, limited access to care, and cost. oVRcome aims to tackle these challenges by providing a cost-effective, accessible, and self-guided treatment option, which can be used independently or alongside therapist support.
Following the trial's success, oVRcome is poised for expansion on an international scale. The programme has participated in several international pilot schemes, including one with the UK's National Health Service (NHS), where it aids autistic patients in familiarising themselves with hospital settings via VR before admission. Adam Hutchinson, Founder of oVRcome, stated, "We're meeting people where they are, bringing accessible, effective treatment to anyone with a smartphone."
See the full article here
